Global Alpha Capital Management Ltd. Makes New Investment in Certara, Inc. $CERT

Global Alpha Capital Management Ltd. acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 172,700 shares of the company’s stock, valued at approximately $1,521,000. Global Alpha Capital Management Ltd. owned approximately 0.11% of Certara as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after acquiring an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Certara in the second quarter worth approximately $83,000. Finally, Curated Wealth Partners LLC acquired a new stake in shares of Certara in the fourth quarter worth approximately $89,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Trading Down 4.3%

Shares of CERT stock opened at $5.37 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $13.88. The company’s 50-day moving average price is $5.63 and its 200-day moving average price is $7.29. The stock has a market cap of $835.41 million, a price-to-earnings ratio of -53.70 and a beta of 1.49.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.24 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Robert W. Baird lowered their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. KeyCorp cut their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Finally, Craig Hallum decreased their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Certara has a consensus rating of “Hold” and an average price target of $8.85.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.